Imaging-Guided Gene Therapy of Experimental Gliomas
Open Access
- 15 February 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (4) , 1706-1715
- https://doi.org/10.1158/0008-5472.can-06-2418
Abstract
To further develop gene therapy for patients with glioblastomas, an experimental gene therapy protocol was established comprising a series of imaging parameters for (i) noninvasive assessment of viable target tissue followed by (ii) targeted application of herpes simplex virus type 1 (HSV-1) amplicon vectors and (iii) quantification of treatment effects by imaging. We show that viable target tissue amenable for application of gene therapy vectors can be identified by multitracer positron emission tomography (PET) using 2-18F-fluoro-2-deoxy-d-glucose, methyl-11C-l-methionine, or 3′-deoxy-3′-18F-fluoro-l-thymidine ([18F]FLT). Targeted application of HSV-1 amplicon vectors containing two therapeutic genes with synergistic antitumor activity (Escherichia coli cytosine deaminase, cd, and mutated HSV-1 thymidine kinase, tk39, fused to green fluorescent protein gene, gfp) leads to an overall response rate of 68%, with 18% complete responses and 50% partial responses. Most importantly, we show that the “tissue dose” of HSV-1 amplicon vector–mediated gene expression can be noninvasively assessed by 9-[4-18F-fluoro-3-(hydroxymethyl)butyl]guanine ([18F]FHBG) PET. Therapeutic effects could be monitored by PET with significant differences in [18F]FLT accumulation in all positive control tumors and 72% in vivo transduced tumors (P = 0.01) as early as 4 days after prodrug therapy. For all stably and in vivo transduced tumors, cdIREStk39gfp gene expression as measured by [18F]FHBG-PET correlated with therapeutic efficiency as measured by [18F]FLT-PET. These data indicate that imaging-guided vector application with determination of tissue dose of vector-mediated gene expression and correlation to induced therapeutic effect using multimodal imaging is feasible. This strategy will help in the development of safe and efficient gene therapy protocols for clinical application. [Cancer Res 2007;67(4):1706–15]Keywords
This publication has 51 references indexed in Scilit:
- Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectorsGene Therapy, 2005
- Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cellsOncogene, 2004
- Improved Herpes Simplex Virus Type 1 Amplicon Vectors for Proportional Coexpression of Positron Emission Tomography Marker and Therapeutic GenesHuman Gene Therapy, 2003
- CL1-SR39: A Noninvasive Molecular Imaging Model of Prostate Cancer Suicide Gene Therapy Using Positron Emission TomographyJournal of Urology, 2002
- Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma modelGene Therapy, 2002
- Tumor-specific transcriptional targeting of suicide gene therapyGene Therapy, 2002
- Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivoNuclear Medicine and Biology, 2000
- A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase "Suicide" Gene Therapy for Recurrent GlioblastomaHuman Gene Therapy, 1998
- Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinaseGene Therapy, 1998
- Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene TherapiesJNCI Journal of the National Cancer Institute, 1998